Continuous Glucose Monitoring

Further, the authors of the “Standards of Care in Diabetes 2025” highlighted the benefits of continuous glucose monitoring systems and recommend initiating these as soon as possible.

Pharmacists have positive impacts on health outcomes for diabetes and patients using CGM devices, including reductions in A1c.

Clinical pharmacists counsel patients during the intervention and make informed medication changes based on the data received from continuous glucose monitoring (CGM).

The integration of CGM into pharmacy practice represents a significant opportunity for pharmacists to provide enhanced patient care.

Heather Johnson, PharmD, BCACP, CTTS, and Heather Roth, BSPharm, RPh, discuss medications and devices used for improving cardiovascular health among patients with or without diabetes.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discusses the various errors patients experience when using CGM devices.

A recent study found that continuous glucose monitors could help improve patient comfort, reduce resource use, and improve outcomes.

However, investigators did not determine the association between compatibility status and loss-of-signal alarms.

App notifications can be effected by various notification focuses, software updates, or connecting hardware, such as car audio or wireless earphones.

Heather Folz, PharmD, BCACP and Christina H. Sherrill, PharmD, BCACP, BC-ADM discuss challenges pharmacists may face when implementing CGM services and how they can help raise awareness.

The Eversense 365 is the world’s first long-term CGM that provides 1 year of use and should be available by the fourth quarter of 2024.

Lingo offers users a real-time glucose graph, a metric to track glucose spikes, food and activity logging, personal recommendations, and challenges to motivate healthy behaviors.

The Stelo glucose biosensor system is intended for use in adults who do not use insulin or in those without diabetes who wish to better understand how diet and exercise affect blood glucose levels.

Medtronic also announced it has entered a global partnership with Abbott in an effort to expand CGM device options for patients living with diabetes.

Patients using isCGM had reduced glucose variability, time in low glucose range, time in very low glucose range, and less events related to low glucose levels.

A pilot study presented at the American Diabetes Association 84th Scientific Sessions showed that CGM technology could produce reliable results without complications in children with leukemia/lymphoma at risk for hyperglycemia.

Research presented at the American Diabetes Association 84th Scientific Sessions suggests a population approach to CGM use could be beneficial.

Catch up on important continuous glucose monitoring (CGM) news from the month of June.

Two posters presented at the American Diabetes Association 84th Scientific Sessions looked at challenges of remote CGM in older populations and after discharge from the hospital.

Two abstracts presented at the American Diabetes Association 84th Scientific Sessions explored how positive user experiences with a CGM can lead to better patient outcomes.

A selection of studies presented at the American Diabetes Association 84th Scientific Sessions examined the use of CGM technology in type 2 diabetes.

Clinical recommendations for the management of type 1 diabetes (T1D) in older adults are urgently needed as the global population ages and as improved diabetes care and management of complications have extended the life expectancy of the patient population.

The Lingo and Libre Rio from Abbott are based on the company’s FreeStyle Libre sensing technology.

In a study presented at ASCO 2024, investigators found that all 20 included patients with early stage breast cancer receiving chemotherapy developed hyperglycemia.

In a session presented at the 2024 Heart in Diabetes Conference, researchers discussed the abilities of continuous glucose monitoring (CGM) to capture lifestyle data and improve mortality rates.

In an abstract presented at ENDO 2024, researchers addressed practitioners’ current knowledge of CGM and their experience prescribing in low-income communities.

HbA1c levels decreased significantly after an average of 154 days in patients who used a continuous glucose monitor.

Catch up on important continuous glucose monitoring (CGM) news from the month of May.

Patients with type 2 diabetes who used continuous glucose monitors combined with regular exercise had improved fasting glucose and 2 hours-postprandial glucose levels.

A report from Dexcom found that depression and anxiety are commonly reported in patients living with type 2 diabetes, but continuous glucose monitors can make disease management easier.